Bookmark and Share

ACCUSOL 35 POTASSIUM 4 Drug Information Page

Updated 08/09/2010 12:50:37 AM

ProductSourceDateLinkData
ACCUSOL 35 POTASSIUM 4MHRA2008-10-2ACCUSOL 35 POTASSIUM 4-MHRA-2008-10-2Further to the Caution in Use issued on 23rd July, ref EL(08)A/9, concerning the above Accusol 35 products, Baxter Healthcare Limited will now be recalling certain batches, as listed on the attached table. Recipients are requested to quarantine any remaining stock whilst arrangements for return and credit are made. Baxter Healthcare Limited has enclosed a reply form with their recall letter, which should be completed and faxed back to them. Recipients of this Drug Alert should bring this information to the attention of Renal Units and Intensive Care Units by copy of this letter.
ACCUSOL 35 POTASSIUM 4MHRA2008-3-28ACCUSOL 35 POTASSIUM 4-MHRA-2008-3-28The MHRA has been informed that some batches of the above Accusol 35 products have formed visible white precipitate during haemofiltration in Continuous Renal Replacement Therapy (CRRT). Advice for Accusol 35 Use in CRRT Therapy Baxter Healthcare advise that pre-dilution and post-dilution lines are inspected at the start of therapy and thereafter at least every 30 minutes during CRRT with Accusol 35 solutions. If any precipitate formation is observed or any adverse reaction is suspected during the use of Accusol 35, please report by telephone to Baxter Healthcare on 01635 206345.

Joining this website will allow you to recieve emails about any pharmaceutial you are interested in or you can search for other pharmaceuticals on this website. Joining should only take 2 minutes.



Image of checkdrugs.com Logo
© Cardan Technologies Inc

This site is presented as an educational source only and you use it at your own risk. The information on this site is not a substitute for a visit with your doctor or pharmacist. Always talk to your doctor before changing medications or dosage, or if you experience any serious side effects.